Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

NEW YORK – Twist Bioscience and enzyme engineering firm Watchmaker Genomics announced Tuesday a partnership on high-throughput applications of next-generation sequencing, including tumor profiling, inherited disease diagnostics, liquid biopsies, and minimal residual disease (MRD) monitoring.

Under the terms of the deal, the partners will create products, the first of which will incorporate Watchmaker's high-fidelity library amplification master mix into Twist's enzymatic library preparation kit.

Other potential application areas include cell-free DNA, circulating tumor DNA, single-cell genomics, low allele somatic variant detection, and tumor mutation burden.

Financial and other details were not disclosed.

"By pairing superior enzymes with best-in-class DNA, we expect to offer differentiated products that simplify and streamline workflows before putting samples on the sequencer," Twist CEO and Cofounder Emily Leproust said in a statement.

Boulder, Colorado-based Watchmaker offers a portfolio of enzymes and kits for NGS library preparation, synthetic biology, and molecular diagnostics.

South San Francisco-based Twist recently launched a NGS Methylation Detection System featuring a new enzymatic alternative to bisulfite conversion from New England Biolabs. Last month, Leproust revealed that Twist has been working on MRD testing and that in Q4 2020 NGS revenues outpaced synthetic biology revenues for the first time in the company's history.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.